Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D03RQW
|
|||
| Former ID |
DIB011896
|
|||
| Drug Name |
Rostaporfin
|
|||
| Synonyms |
Photrex; Purlytin; Rostaporfine; Tin ethyl etiopurpurin dichloride; Tin etiopurpurin dichloride; Photopoint SnET2; SnET2; PNU-167524; PNU-524-OPT-0065
Click to Show/Hide
|
|||
| Drug Type |
Small molecular drug
|
|||
| Indication | Macular degeneration [ICD-11: 9B78.3; ICD-10: H35.3; ICD-9: 362.5] | Phase 3 | [1], [2] | |
| Breast cancer [ICD-11: 2C60-2C65] | Phase 2 | [3] | ||
| Basal cell carcinoma [ICD-11: 2C32; ICD-10: C44] | Phase 1 | [3], [4] | ||
| Solid tumour/cancer [ICD-11: 2A00-2F9Z; ICD-10: C76-C80; ICD-9: 140-229] | Phase 1 | [3] | ||
| Company |
Miravant Medical Technologies
|
|||
| Structure |
 |
Download2D MOL |
||
| Formula |
C37H42Cl2N4O2Sn
|
|||
| Canonical SMILES |
CCC1=C(C2=CC3=C(C(=C4N3[Sn](N5C(=CC1=N2)C(C6(C5=C(C=C6C(=O)OCC)C7=NC(=C4)C(=C7C)CC)CC)C)(Cl)Cl)C)CC)C
|
|||
| InChI |
1S/C37H43N4O2.2ClH.Sn/c1-10-23-19(6)29-17-33-25(12-3)21(8)34(40-33)26-15-27(36(42)43-14-5)37(13-4)22(9)30(41-35(26)37)18-32-24(11-2)20(7)28(39-32)16-31(23)38-29;;;/h15-18,22H,10-14H2,1-9H3,(H-,38,39,40,41,42);2*1H;/q-1;;;+4/p-3/t22-,37+;;;/m0.../s1
|
|||
| InChIKey |
MCTOGTBIQBEIBZ-RHJKTMSGSA-K
|
|||
| PubChem Compound ID | ||||
| References | Top | |||
|---|---|---|---|---|
| REF 1 | ClinicalTrials.gov (NCT00157976) Double-Masked Study of Photrex (Rostaporfin) Photodynamic Therapy in the Treatment of Age-Related Macular Degeneration. U.S. National Institutes of Health. | |||
| REF 2 | Rostaporfin (Miravant Medical Technologies). IDrugs. 2002 Feb;5(2):180-6. | |||
| REF 3 | Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) | |||
| REF 4 | Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.